GynOnc Expert Insight

CE / CME

Key Advances in Gynecologic Cancers: Expert Insight for Incorporating New Clinical Evidence

Pharmacists: 1.25 contact hours (0.125 CEUs)

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Nurses: 1.25 Nursing contact hours

Released: May 13, 2022

Expiration: May 12, 2023

Eva Y. Pan
Eva Y. Pan, PharmD, BCOP
Ritu Salani
Ritu Salani, MD, MBA

Activity

Progress
1
Course Completed

In this module, Ritu Salani, MD, MBA, and Eva Y. Pan, PharmD, BCOP, discuss the rapidly evolving treatment landscape for ovarian, endometrial, and cervical cancers. Their discussion covers current guideline recommendations on biomarker use in ovarian cancer, individualizing therapy for endometrial cancer, and emerging new data and recent approvals in cervical cancer, as well as a pharmacist’s perspectives on the management of all 3 tumor types using the latest treatment advances.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with gynecologic cancers do you provide care for in a typical month?
Which of the following best describes your role on the patient care team?
Your patient with BRCA-mutated, recurrent ovarian cancer achieved a partial response to carboplatin and paclitaxel chemotherapy (CT) rechallenge. Which of the following PARP inhibitor(s) would be an appropriate maintenance therapy choice for her?

Your patient with endometrial cancer previously achieved a complete response after 7 cycles of carboplatin and paclitaxel 1 year ago. She is now experiencing signs of disease progression (eg, stomach bloating and pain, unplanned weight loss, and right/left inguinal lymphadenopathy). On imaging, she has enlarged bilateral pelvic masses compared with a previous baseline scan.

Which of the following biomarkers would you assess to determine whether this patient with recurrent advanced endometrial cancer is eligible for single-agent (dostarlimab or pembrolizumab) or combination immunotherapy (lenvatinib plus pembrolizumab)?
Carmen is a 45-year-old patient previously diagnosed with high-grade, microsatellite stable (MSS), HER2-negative endometrial cancer. She previously was treated with paclitaxel/carboplatin but recently experienced disease progression. Carmen also has diabetes, but it is adequately controlled with medication.